Janssen

MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
Flag link:
FDA Gives Greenlight to Janssen and AbbVie's Imbruvica for the 10th Time
FDA Gives Greenlight to Janssen and AbbVie's Imbruvica for the 10th Time
BioSpace
Imbruvica
Janssen
AbbVie
Roche
Gazyva
chronic lymphocytic leukemia
small lymphocytic lymphoma
FDA
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
patents
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys
Janssen
Genmab
Flag link:
Apple and Johnson & Johnson collaborating on heart research project
Apple and Johnson & Johnson collaborating on heart research project
Marketwatch
Apple
JNJ
Janssen
atrial fibrillation
Apple Watch
wearables
devices
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
CP Wire
Janssen
JNJ
Erleada
prostate cancer
Europe
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
Janssen
JNJ
Erleada
prostate cancer
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November
Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November
Motley Fool
Arrowhead Pharmaceuticals
ARO-HBV
hepatitis B
Janssen
RNAi
Flag link:
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
Fierce Biotech
Argenx
Cilag
Janssen
cusatuzumab
ASH2018
blood cancers
Flag link:
Adaptive Trial Designs: BIO, Janssen, ACRO Call for Tweaks to FDA Draft Guidance
Adaptive Trial Designs: BIO, Janssen, ACRO Call for Tweaks to FDA Draft Guidance
RAPS.org
clinial trials
adaptive trial design
FDA
BIO
ACRO
Janssen
Flag link:
New Jersey Sues Janssen Pharmaceuticals Over Two Opioid Drugs
New Jersey Sues Janssen Pharmaceuticals Over Two Opioid Drugs
BioSpace
New Jersey
opioids
JNJ
Janssen
Flag link:
Llama antibodies could provide universal flu protection
Llama antibodies could provide universal flu protection
BioCentury
Janssen
Scripps Research Institute
flu vaccines
Flu
Flag link:
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Forbes
Janssen
JNJ
Invokana
type 2 diabetes
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
CP Wire
Arrowhead Pharmaceuticals
Janssen
JNJ
hepatitis B
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals
Janssen
JNJ
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
CP Wire
Janssen
JNJ
Symtuza
HIV
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen
JNJ
Symtuza
HIV
Flag link:

Pages